関連する実験動画
Updated: Sep 10, 2025

11:19
Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
17.7K
メフェナミク酸の小児医療における使用に関するコンセンサス (MAPP):インドの小児科医の見解
Uday Pai1, Ravishankar A Venkata2, Abhay Shah3
1Department of Pediatrics, Sai Kutir Clinic, Mumbai, IND.
Cureus
|August 25, 2025
まとめ
メフェナミク酸は,他のNSAIDと比較して,子供に優れた発熱と痛みを和らげます. 専門家のコンセンサスは,安全で効果的な小児使用のためのベストプラクティスガイドラインを提供していますが,長期的な安全性データが必要です.
科学分野:
- 小児薬学
- 非ステロイド抗炎症薬 (NSAID)
- 痛みと発熱の管理
背景:
- 熱と痛みは,安全な管理を必要とする一般的な小児の苦情です.
- NSAIDであるメフェナミク酸は,COX - 2抑制とNLRP3炎症体の抑制を含むユニークな性質を持っています.
- 限られた小児ガイドラインと安全性の懸念は,メフェナミク酸の日常的な使用を妨げています.
研究 の 目的:
- 小児の治療におけるメフェナミク酸に関する実証に基づいたベストプラクティス勧告を策定する.
- 子供におけるメフェナミク酸の安全性,有効性,および臨床応用を評価する.
- 小児ガイドラインのギャップと安全性の懸念を解決する.
主な方法:
- 構造化された変更されたデルフィープロセスが採用された.
- インドから21人の小児科医が参加した.
- このコンセンサスは,メフェナミク酸の使用に関する既存の証拠を評価した.
主要な成果:
- メフェナミク酸は,パラセタモールとイブプロフェンよりも高い発熱抑制効果を示した.
- 臨床前データは,抗ウイルス作用と熱性発作における役割を示唆している.
- メフェナミク酸は,適切な使用で好ましい安全性プロファイルを示しています.
結論:
- コンセンサスでは,小児科でのメフェナミク酸の使用を最適化するための枠組みを提供します.
- 長期的な安全性を確認し,治療範囲を拡大するためにさらなる研究が必要です.
- 6ヶ月から5歳までの子供には 強力な試験が不可欠です
関連する概念動画
Tonsillitis II: Management
175
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
175
Acute Kidney Injury V: Interprofessional Care
44
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
44
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
Rheumatic Heart Disease III: Medical Management
32
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
32
Parenteral Anesthetics: Overview
196
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
196

